| Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus R Furie, VP Werth, JF Merola, L Stevenson, TL Reynolds, H Naik, ... The Journal of clinical investigation 129 (3), 1359-1371, 2019 | 222 | 2019 |
| Development and validation of a high-performance liquid chromatography–mass spectroscopy assay for determination of artesunate and dihydroartemisinin in human plasma H Naik, DJ Murry, LE Kirsch, L Fleckenstein Journal of Chromatography B 816 (1-2), 233-242, 2005 | 118 | 2005 |
| The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate H Naik, J Wu, R Palmer, L McLean British journal of clinical pharmacology 74 (2), 327-335, 2012 | 108 | 2012 |
| Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK‐875: results from a double‐blind, placebo‐controlled single oral dose rising … H Naik, M Vakilynejad, J Wu, P Viswanathan, N Dote, T Higuchi, E Leifke The Journal of Clinical Pharmacology 52 (7), 1007-1016, 2012 | 104 | 2012 |
| Population pharmacokinetic meta‐analysis of vortioxetine in healthy individuals J Areberg, KB Petersen, G Chen, H Naik Basic & clinical pharmacology & toxicology 115 (6), 552-559, 2014 | 98 | 2014 |
| A multiple‐ascending‐dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK‐875, in subjects with type 2 diabetes E Leifke, H Naik, J Wu, P Viswanathan, D Demanno, M Kipnes, ... Clinical Pharmacology & Therapeutics 92 (1), 29-39, 2012 | 95 | 2012 |
| Trial of anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus VP Werth, RA Furie, J Romero-Diaz, S Navarra, K Kalunian, ... New England Journal of Medicine 387 (4), 321-331, 2022 | 60 | 2022 |
| Population pharmacokinetics of artesunate and dihydroartemisinin following single-and multiple-dosing of oral artesunate in healthy subjects B Tan, H Naik, IJ Jang, KS Yu, LE Kirsch, CS Shin, JC Craft, ... Malaria journal 8, 1-13, 2009 | 30 | 2009 |
| Design of phase 3 studies evaluating vixotrigine for treatment of trigeminal neuralgia M Kotecha, WP Cheshire, H Finnigan, K Giblin, H Naik, J Palmer, S Tate, ... Journal of Pain Research, 1601-1609, 2020 | 22 | 2020 |
| Development and validation of a liquid chromatography–mass spectrometry assay for the determination of pyronaridine in human blood for application to clinical pharmacokinetic … H Naik, P Imming, MS Schmidt, DJ Murry, L Fleckenstein Journal of pharmaceutical and biomedical analysis 45 (1), 112-119, 2007 | 21 | 2007 |
| Characterization of vixotrigine, a broad-spectrum voltage-gated sodium channel blocker CA Hinckley, Y Kuryshev, A Sers, A Barre, B Buisson, H Naik, M Hajos Molecular Pharmacology 99 (1), 49-59, 2021 | 18 | 2021 |
| Pharmacometric approaches to guide dose selection of the novel GPR40 agonist TAK‐875 in subjects with type 2 diabetes mellitus H Naik, J Lu, C Cao, M Pfister, M Vakilynejad, E Leifke CPT: pharmacometrics & systems pharmacology 2 (1), 1-10, 2013 | 17 | 2013 |
| Discovery of vixotrigine: a novel use-dependent sodium channel blocker for the treatment of trigeminal neuralgia DR Witty, G Alvaro, D Derjean, GMP Giblin, K Gunn, C Large, ... ACS Medicinal Chemistry Letters 11 (9), 1678-1687, 2020 | 15 | 2020 |
| The effects of xanthine oxidase inhibition by febuxostat on the pharmacokinetics of theophylline. M Tsai, J Wu, L Gunawardhana, H Naik International journal of clinical pharmacology and therapeutics 50 (5), 331-337, 2012 | 15 | 2012 |
| A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans K Biliouris, I Nestorov, H Naik, D Dai, G Xiao, Q Wang, A Pellerin, ... Journal of pharmacokinetics and pharmacodynamics 45, 817-827, 2018 | 12 | 2018 |
| A population pharmacokinetic–pharmacodynamic meta‐analysis of vortioxetine in patients with major depressive disorder H Naik, S Chan, M Vakilynejad, G Chen, H Loft, AR Mahableshwarkar, ... Basic & Clinical Pharmacology & Toxicology 118 (5), 344-355, 2016 | 12 | 2016 |
| A clinical population pharmacokinetic/pharmacodynamic model for BIIB059, a monoclonal antibody for the treatment of systemic and cutaneous lupus erythematosus S Hartmann, K Biliouris, H Naik, D Rabah, L Stevenson, C Shen, ... Journal of Pharmacokinetics and Pharmacodynamics 47, 255-266, 2020 | 8 | 2020 |
| Methods for concomitant treatment of theophylline and febuxostat L Gunawardhana, M Tsai, H Naik US Patent App. 13/282,659, 2012 | 8 | 2012 |
| Bioequivalence of intramuscular and subcutaneous peginterferon beta-1a: results of a phase I, open-label crossover study in healthy volunteers Y Zhao, K Chen, N Ramia, S Sahu, A Kumar, ML Naylor, L Zhu, H Naik, ... Therapeutic Advances in Neurological Disorders 14, 1756286420975227, 2021 | 7 | 2021 |
| Evaluation of the pharmacokinetic interaction between the voltage‐and use‐dependent Nav1. 7 channel blocker vixotrigine and carbamazepine in healthy volunteers J Dunbar, M Versavel, Y Zhao, S Tate, V Morisset, GMP Giblin, J Palmer, ... Clinical Pharmacology in Drug Development 9 (1), 62-73, 2020 | 7 | 2020 |
